Clinical Trials for Mesothelioma Patients—Vaccine Therapy and GM-CSF: Study Objectives

Read about the objectives of a concurrent therapy for a current clinical trial to test vaccine therapy GM-CSF on mesothelioma patients. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Primary Objectives:

• Determine the safety and immunogenicity of the Wilms tumor-1 analog peptide vaccine in patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma.

Secondary Objectives:

• Determine the antitumor effects of this vaccine in these patients.

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.